ARV Therapies and Therapeutic Strategies

REPORTING ON EACS 2015

Comprehensive Expert Review and Discussion of Key Presentations

An Independent CME Activity Jointly Provided by Postgraduate Institute for Medicine and ViralEd, Inc.

The coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.

Sofosbuvir Plus Ledipasvir for 8 Weeks in HCV-mono- and HIV-HCV-coinfected Patients - Results from the German Hepatitis C Cohort (GECCO)

P. Ingiliz, S. Christensen, S. Mauss, D. Hueppe, T. Kimhofer, K.-G. Simon, J.K. Rockstroh, H.W. Busch, G. Schmutz, A. Baumgarten, K. Schewe, T. Lutz

Abstract PS7/5

Results

- To date, 1157 patients had been started on DAA regimens in 8 sites
- 282 (24.4%) HIV-HCV coinfected

→ 148 (13%) were treated with SL8



Ingiliz P, et al; 15th EACS, Barcelona, Spain, October 21-24, 2015; Abst. PS7/5

GECCO Cohort - Ledipasvir/Sofosbuvir 8 Weeks: Baseline Characteristics

	Overall (n=148)	HCV (n=120)	HIV-HCV (n=28)	p
Male sex, n(%)	72 (49)	49 (41)	23 (82)	<0.001
Median age [years] (IQR)	52 (44-58)	54 (45-62)	50 (42-62)	0.01
Transmission IVDU/MSM/blood, n(%)	46(31)/15(10)/ 36(24)	39(33)/1(1)/39(33)	7(25)/14(50)/0	<0.01
HCV genotype 1/4, n(%)	144(97)/3(2)	120 (100)	24(86)/3(11)	<0.001
Median HCV viral load [IU/mL] (IQR)	$8.1x10^5$ ($2.5x10^5$-$1.7x10^6$)	$9x10^5$ ($3.4x10^5$-$1.7x10^6$)	$4.9x10^5$ ($8x10^4$-$9.8x10^5$)	0.01
Median ALT [U/L] (IQR)	56 (37-89)	53 (36-80)	78 (49-166)	<0.01
Prior HCV treatment, n (%)	26 (18)	22 (18)	4 (14)	ns
Fibroscan >12.5kPa or APRI >2, n(%)	5 (3)	3 (3)	2 (7)	
HIV coinfection, n (%)	28 (19)	0 (0)	28 (100)	
Median CD4 cell count [/mm^3] (IQR)	531 (346-683)	NA	531 (346-683)	

Ingiliz P, et al; 15th EACS, Barcelona, Spain, October 21-24, 2015; Abst. PS7/5

HCV Viral Load at Baseline, SL8

- Baseline HCV RNA measured with two different assays in patients treated with sofosbuvir-ledipasvir for 8 weeks



4 sites used Roche Taqman v 2.0 (n=79), 3 sites used Abbott Real Time PCR (n=54), one site used both

Ingiliz P, et al; 15th EACS, Barcelona, Spain, October 21-24, 2015; Abst. PS7/5

GECCO Cohort: Results – Efficacy SVR4



Ingiliz P, et al; 15th EACS, Barcelona, Spain, October 21-24, 2015; Abst. PS7/5

GECCO Cohort: Results – Efficacy SVR12



Ingiliz P, et al; 15th EACS, Barcelona, Spain, October 21-24, 2015; Abst. PS7/5

Safety SL8

- Side effects in patients treated with sofosbuvir-ledipasvir for 8 weeks
- No discontinuations

	n (%)
Headache	14 (10)
Fatigue	11 (7)
Nausea	4 (3)
Arthralgia	3 (2)

Ingiliz P, et al; 15th EACS, Barcelona, Spain, October 21-24, 2015; Abst. PS7/5